XTL Biopharmaceuticals Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	2018 - 2014
Period Ending	Sep '24 Sep 12, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	2018 - 2014
Market Capitalization	122	19	22	47	50	24	Upgrade
Market Cap Growth	138.10%	-14.63%	-52.02%	-7.60%	108.51%	-31.88%	Upgrade
Enterprise Value	114	11	7	37	38	8	Upgrade
Last Close Price	0.10	0.04	0.04	0.09	0.10	0.05	Upgrade
PE Ratio	-	-2.97	-4.71	39.16	-5.08	-9.18	Upgrade
PB Ratio	5.46	2.39	1.59	2.81	4.34	1.07	Upgrade
P/FCF Ratio	-	-7.49	-7.05	-14.27	-18.42	-7.69	Upgrade
P/OCF Ratio	-	-7.49	-7.05	-14.27	-18.44	-7.71	Upgrade
EV/EBITDA Ratio	-	-3.87	-2.17	-11.50	-12.33	-	Upgrade
EV/EBIT Ratio	-18.11	-3.87	-2.17	-11.49	-12.32	-2.76	Upgrade
EV/FCF Ratio	-	-4.19	-2.12	-11.29	-13.73	-2.55	Upgrade
Quick Ratio	10.49	9.74	19.90	26.52	23.79	29.00	Upgrade
Current Ratio	11.43	9.93	20.35	27.00	24.10	29.44	Upgrade
Return on Equity (ROE)	-13.07%	-57.31%	-28.89%	9.73%	-58.34%	-11.07%	Upgrade
Return on Assets (ROA)	-13.78%	-14.46%	-10.18%	-9.82%	-8.64%	-6.67%	Upgrade
Return on Capital (ROIC)	-14.89%	-15.38%	-11.79%	-14.41%	-11.70%	-7.63%	Upgrade
Earnings Yield	-2.56%	-33.65%	-21.22%	2.91%	-18.85%	-10.90%	Upgrade
FCF Yield	-13.35%	-14.18%	-7.01%	-5.43%	-13.01%	Upgrade
Buyback Yield / Dilution	0.00%	11.48%	-19.71%	-	-	Upgrade
Total Shareholder Return	0.00%	11.48%	-19.71%	-	-	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.